Myelodysplastic syndrome presenting as third malignancy after non-Hodgkin's lymphoma and osteosarcoma

The patient was initially diagnosed as having non-Hodgkin's lymphoma and was cured following treatment with prednisolone, vincristine, daunorubicin, 1-asparaginase, and cyclophosphamide. Seven years and two months later, he developed osteosarcoma in his right femur. He received chemotherapy con...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 1997-02, Vol.74 (2), p.95-97
Main Authors: KUBOTA, M, SAWADA, M, WATANABE, K, KOISHI, S, KATAOKA, A, USAMI, I, LIN, Y. W, OKUDA, A, AKIYAMA, Y, FURUSHO, K
Format: Article
Language:English
Subjects:
Adolescent
Antineoplastic Agents, Alkylating - adverse effects
Biological and medical sciences
Chromosome Aberrations - etiology
Chromosome Disorders
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Drug toxicity and drugs side effects treatment
Humans
Karyotyping
Lymphoma, Non-Hodgkin - diagnosis
Male
Medical sciences
Miscellaneous (drug allergy, mutagens, teratogens...)
Myelodysplastic Syndromes - chemically induced
Myelodysplastic Syndromes - diagnosis
Myelodysplastic Syndromes - genetics
Osteosarcoma - diagnosis
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The patient was initially diagnosed as having non-Hodgkin's lymphoma and was cured following treatment with prednisolone, vincristine, daunorubicin, 1-asparaginase, and cyclophosphamide. Seven years and two months later, he developed osteosarcoma in his right femur. He received chemotherapy consisting of methotrexate, carboplatin, etoposide, and ifosfamide and again obtained remission. After 2 years and 7 months, however, he was found to have pancytopenia with morphological abnormalities in the erythroid and myeloid series. Diagnosis of myelodysplastic syndrome (MDS) was made. Cytogenetic analysis of bone marrow cells revealed -5 and -7, which is typical for secondary MDS. This is a rare case of third malignancy presumably caused by alkylating agents.
ISSN:0939-5555
1432-0584
DOI:10.1007/s002770050264